Results 161 to 170 of about 141,326 (319)

Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease

open access: bronze, 1998
Christophe Piketty   +11 more
openalex   +1 more source

Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy [PDF]

open access: bronze, 1997
Pere Domingo   +3 more
openalex   +1 more source

The role of acquired host immunity in periodontal diseases

open access: yesPeriodontology 2000, EarlyView.
Abstract The aim of this narrative review is to relate the contribution of European researchers to the complex topic of the host immune system in periodontal disease, focusing on acquired immunity. Other chapters in this volume will address the genetics and autoantibody responses and other forms of immunity to periodontal disease.
Denis F. Kinane   +2 more
wiley   +1 more source

The miRNomics of antiretroviral therapy-induced obesity. [PDF]

open access: yesFunct Integr Genomics
Majumdar N   +7 more
europepmc   +1 more source

Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds [PDF]

open access: bronze, 1995
Maria Carla Re   +9 more
openalex   +1 more source

Critical Care Pharmacology of Antiretroviral Therapy in Adults. [PDF]

open access: yesEur J Drug Metab Pharmacokinet
La Via L   +9 more
europepmc   +1 more source

Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

open access: bronze, 1999
Jan M. Prins   +13 more
openalex   +1 more source

Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study

open access: yesClinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1393-1402, May 2025.
Ritonavir‐boosted atazanavir is a victim of drug–drug interaction with rifampicin, a key component of antitubercular treatment. In a recent dose escalation clinical trial, we showed that increasing atazanavir/ritonavir to 300/100 mg b.i.d. compensates for reduced drug exposure in plasma due to rifampicin, but the intracellular effects remained ...
Amedeo De Nicolò   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy